tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuritis D009443 4 associated lipids
Neurodermatitis D009450 1 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neutropenia D009503 15 associated lipids
Nocardia Infections D009617 6 associated lipids
Obesity D009765 29 associated lipids
Oliguria D009846 2 associated lipids
Opportunistic Infections D009894 8 associated lipids
Optic Neuritis D009902 1 associated lipids
Orchitis D009920 1 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Osteomalacia D010018 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteoporosis D010024 12 associated lipids
Ovarian Cysts D010048 4 associated lipids
Pain D010146 64 associated lipids
Pain, Intractable D010148 4 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Pancytopenia D010198 6 associated lipids
Paraproteinemias D010265 2 associated lipids
Paresis D010291 2 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotitis D010309 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Pemphigus D010392 3 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Pericarditis D010493 6 associated lipids
Periodontal Pocket D010514 9 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Pharyngitis D010612 2 associated lipids
Pityriasis D010915 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Postoperative Complications D011183 5 associated lipids
Poxviridae Infections D011213 1 associated lipids
Precancerous Conditions D011230 48 associated lipids
Pregnancy Complications D011248 19 associated lipids
Priapism D011317 1 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pruritus Ani D011538 2 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Psoriasis D011565 47 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pterygium D011625 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Rectal Diseases D012002 1 associated lipids
Rectal Fistula D012003 2 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Respiration Disorders D012120 5 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Retinoblastoma D012175 12 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rosacea D012393 13 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rupture D012421 2 associated lipids
Sarcoidosis D012507 13 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Osteosarcoma D012516 50 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Sclerosis D012598 5 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Seizures D012640 87 associated lipids
Shock D012769 11 associated lipids
Shock, Septic D012772 11 associated lipids
Sinusitis D012852 9 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Skin Neoplasms D012878 12 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomatitis D013280 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Tachycardia D013610 7 associated lipids
Telangiectasis D013684 2 associated lipids
Testicular Diseases D013733 15 associated lipids
Thinness D013851 11 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombosis D013927 49 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Tinea D014005 5 associated lipids
Tinea Capitis D014006 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Finn L et al. Epstein-Barr virus infections in children after transplantation of the small intestine. 1998 Am. J. Surg. Pathol. pmid:9500771
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Minervini MI et al. Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). 2000 Am. J. Surg. Pathol. pmid:10757402
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Lehmann R et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. 2004 Am. J. Transplant. pmid:15196070
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Latran M Response to Klintmalm on the use of generic immunosuppression. 2012 Am. J. Transplant. pmid:22176636
Ellis CL and Racusen LC Mild rise in creatinine six months post kidney transplant. 2012 Am. J. Transplant. pmid:22845913
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Krenzien F et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. 2017 Am. J. Transplant. pmid:27754593
Borrows R et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. 2004 Am. J. Transplant. pmid:15476485
Hernández-Fisac I et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. 2007 Am. J. Transplant. pmid:17725683
Hirsch HH et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. 2013 Am. J. Transplant. pmid:23137180
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Shihab FS et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. 2013 Am. J. Transplant. pmid:23167508
Alloway RR et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. 2012 Am. J. Transplant. pmid:22759200
Wlodarczyk Z et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. 2009 Am. J. Transplant. pmid:19681813
Hesselink DA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. 2005 Am. J. Transplant. pmid:15816878
Byrne GW et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. 2005 Am. J. Transplant. pmid:15816881
Lucey MR et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 2005 Am. J. Transplant. pmid:15816894
Pillebout E et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). 2005 Am. J. Transplant. pmid:15816895
Sindhi R et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. 2005 Am. J. Transplant. pmid:15636616
Shergill AK et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. 2005 Am. J. Transplant. pmid:15636619
Tydén G et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. 2005 Am. J. Transplant. pmid:15636623
Woodle ES et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. 2005 Am. J. Transplant. pmid:15636625
Mian AN et al. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. 2005 Am. J. Transplant. pmid:15636628
Gregoor PS and Weimar W Tacrolimus and pure red-cell aplasia. 2005 Am. J. Transplant. pmid:15636632
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Padiyar A et al. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. 2010 Am. J. Transplant. pmid:20055793
Hardinger KL et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. 2010 Am. J. Transplant. pmid:20055811
Pondrom S The AJT report. 2008 Am. J. Transplant. pmid:18324976
Fan DM et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. 2015 Am. J. Transplant. pmid:25808777
Mazariegos GV et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. 2005 Am. J. Transplant. pmid:15643991
Knechtle SJ et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 2009 Am. J. Transplant. pmid:19344431
Bahra M et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. 2005 Am. J. Transplant. pmid:15644002
Min SI et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. 2013 Am. J. Transplant. pmid:23734831
Bunnapradist S et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. 2013 Am. J. Transplant. pmid:23279614
Ceschi A et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. 2013 Am. J. Transplant. pmid:23279718
Kaplan B and Kirk AD Tacrolimus and sirolimus: when bad things happen to good drugs. 2006 Am. J. Transplant. pmid:16827845
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Shapiro R et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. 2007 Am. J. Transplant. pmid:17908272
Rush D et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. 2007 Am. J. Transplant. pmid:17908280
Tricot L et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. 2009 Am. J. Transplant. pmid:19519819
Kofler S et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. 2009 Am. J. Transplant. pmid:19519820
Barbas AS et al. Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 2013 Am. J. Transplant. pmid:23331705
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923